AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2887418
Drug: Isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide 5‐mononitrate (Imdur) 60mg once daily
Trial: 24076415
Drug: Ever daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ever daily smoking
Trial: 24076415
Drug: Age at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age at diagnosis for ever daily smokers
Trial: 9717593
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg i.v.)
Trial: 11731754
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg i.v.) followed by Ketorolac (30 mg)
Trial: 11731754
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg i.v.)
Trial: 9040549
Drug: Similac with
RxNorm normalized name: Similac with Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similac with Iron (iron approximately 215 mumol/L or 12 mg/L)
Trial: 2889255
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg once daily at bedtime for 4 weeks
Trial: 19652072
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/d
Trial: 26327301
Drug: Siltuximab (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Siltuximab (11 mg/kg administered intravenously every 3 weeks, or every 6 weeks at investigator's discretion)
Trial: 23204550
Drug: Neridronate 100
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neridronate 100 mg i.v. infusion given four times over 10 days
Trial: 21753156
Drug: LY2334737 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2334737 monotherapy (40 mg)
Trial: 21753156
Drug: LY2334737 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2334737 in combination with erlotinib (100 mg)
Trial: 21753156
Drug: LY2334737 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2334737 monotherapy
Trial: 21753156
Drug: LY2334737 drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2334737 drug formulations
Trial: 19192477
Drug: Intramuscular second-generation
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular second-generation antipsychotics (SGAs)
Trial: 24267729
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and aspirin
Trial: 18664984
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (CIP) for 6-8 weeks
Trial: 18664984
Drug: Topical framycetin-gramicidin-dexamethasone
RxNorm normalized name: framycetin / gramicidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical framycetin-gramicidin-dexamethasone (FGD) for 6-8 weeks
Trial: 14756388
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g
Trial: 15976212
Drug: Acetaminophen 1
RxNorm normalized name: acetaminophen 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 g and Propacetamol 2 g
Trial: 18254326
Drug: Budesonide aqueous
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aqueous nasal spray
Trial: 3920066
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) solution
Trial: 8765824
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (beclomethasone dipropionate (BD) ointment)
Trial: 1913269
Drug: Conventional ragweed
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ragweed preparation (Pool 2)
Trial: 27019001
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg and Everolimus 10 mg, both once daily for 4 weeks (1 cycle)
Trial: 24285427
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg vitamin K1 orally thrice weekly
Trial: 18210952
Drug: High compression
RxNorm normalized name: BANDAGE,HIGH COMPRESSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High compression therapy alone
Trial: 15526982
Drug: triptorelin (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triptorelin (GnRH agonist)
Trial: 15526982
Drug: ganirelix (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganirelix (GnRH antagonist)
Trial: 9591441
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream or ointment applied to lesional skin twice daily for 7-19 days
Trial: 7814359
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment (3-6 months)
Trial: 7814359
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment (6-24 months)
Trial: 28498853
Drug: DAR-901 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAR-901 (1 mg)
Trial: 26071347
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of HPV-16/18 vaccine
Trial: 26071347
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV-16/18 vaccine
Trial: 26071347
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of HPV-16/18 vaccine
Trial: 26071347
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV-16/18 vaccine (second dose at 6 months)
Trial: 26071347
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV-16/18 vaccine (second dose at 1 month)
Trial: 22162639
Drug: Oxy-ER (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy-ER (5 mg)
Trial: 22162639
Drug: Oxy-CRF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy-CRF (5 mg)
Trial: 22162639
Drug: Oxy-CRF (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy-CRF (40 mg)
Trial: 22162639
Drug: Oxy-CRF (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy-CRF (40 mg) after high-fat breakfast
Trial: 12567387
Drug: HFA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA treatment
Trial: 12567387
Drug: Gastrointestinal absorption
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrointestinal absorption of BDP
Trial: 12567387
Drug: 17‐BMP metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17‐BMP metabolism
Trial: 12567387
Drug: i.v. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. administration of BDP
Trial: 8710419
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment with levamisole every 4 months
Trial: 8710419
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment with levamisole at two 6-monthly intervals
Trial: 8710419
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment with levamisole once in 1 year
Trial: 2000046
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C 20 mg/100 mg
Trial: 2000046
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C 10 mg/200 mg
Trial: 2000046
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C 20 mg/200 mg
Trial: 2000046
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + C 10 mg/200 mg and E + C 20 mg/100 mg
Trial: 6392050
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg molsidomine
Trial: 6393621
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg molsidomine
Trial: 6393621
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg and 6 mg molsidomine
Trial: 6393621
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg molsidomine administered 5-6 times daily or 4-6 mg applied 4-5 times daily
Trial: 3402013
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral premedication (meperidine 1.5 mg.kg‐1, diazepam 0.15 mg.kg‐1, atropine 0.02 mg.kg‐1)
Trial: 27147617
Drug: Formoterol (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (54 μg)
Trial: 23727135
Drug: Dopamine D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2 receptor occupancy levels
Trial: 23727135
Drug: Dopamine D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2 receptor occupancy cut-off point
Trial: 16432682
Drug: Quetiapine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (50 mg)
Trial: 9505989
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg)
Trial: 1321654
Drug: Haloperidol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3 mg)
Trial: 30519898
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen
Trial: 21343383
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral capsules, twice daily for 18 days)
Trial: 16832318
Drug: dexmethylphenidate extended-release
RxNorm normalized name: dexmethylphenidate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmethylphenidate extended-release (d-MPH-ER)
Trial: 12708604
Drug: Dexibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexibuprofen 800 mg daily
Trial: 20525840
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg daily
Trial: 10362151
Drug: Spermicidal film
RxNorm normalized name: lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spermicidal film containing 72 mg of nonoxynol-9 per film
Trial: 10362151
Drug: Foaming tablet
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foaming tablet containing 100 mg of nonoxynol-9 per tablet
Trial: 7042364
Drug: Indoprofen (IP)
RxNorm normalized name: Neoprofen
DrugBank: Indoprofen (DB08951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (IP) 800 mg/die
Trial: 26272770
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg, every 3 weeks for six cycles) with neoadjuvant chemotherapy
Trial: 16598591
Drug: Isosorbide-dinitrate (ISDN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide-dinitrate (ISDN) 20 mg b.i.d.
Trial: 15224025
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g as 20-minute bolus before skin incision, followed by continuous infusion of 400 mg/h, with 500 mg added to priming in on-pump patients)
Trial: 15224025
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution of equivalent volume)
Trial: 27062948
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment as usual, delayed treatment (DT) control
Trial: 25690404
Drug: Pulsed RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed RF EMF exposure (900 MHz, 2 Hz pulse, 20 Hz Gaussian low-pass filter, spatial peak absorption of 2 W/kg averaged over 10 g) for 30 minutes prior to sleep
Trial: 12712239
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated) 24 micro g/kg per hour for 96 h
Trial: 10344368
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol with cyclic addition of noretisterone acetate (n = 13)
Trial: 24140142
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection
Trial: 18468378
Drug: Drug reimbursement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug reimbursement rate reduction policy
Trial: 15998783
Drug: Pancreatic polypeptide
RxNorm normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic polypeptide (PP) infusion at 2.25 pmol/kg.min
Trial: 7871082
Drug: diazepam 0.2
RxNorm normalized name: diazepam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 0.2 mg/kg
Trial: 7871082
Drug: lorazepam 0.038
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam 0.038 mg/kg
Trial: 6446691
Drug: Aminooxyacetic acid
DrugBank: Aminooxyacetic acid (DB02079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminooxyacetic acid (AOAA) at a dosage of 2 mg per kilogram per day
Trial: 6408155
Drug: Nomifensine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (200 mg po)
Trial: 24895878
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (n = 167)
Trial: 24895878
Drug: Intravenous tissue-plasminogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue-plasminogen activator (IV tPA) (n = 23)
Trial: 15838889
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (TAC + corticosteroids)
Trial: 15838889
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TAC + corticosteroids + AZA)
Trial: 12492189
Drug: Conventional Colonoscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Colonoscope (CC)
Trial: 10458221
Drug: Epirubicin 200
RxNorm normalized name: epiRUBicin 200 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 200 mg/m2 and cyclophosphamide 4 g/m2 with progenitor cell and filgrastim support every 28 days (n = 79) or 21 days (n = 20)
Trial: 11014391
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (MO) plus Flumazenil (FL) (MO 2 mg + FL 0.2 mg)
Trial: 11014391
Drug: Morphine (MO)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (MO) only (MO 2 mg)
Trial: 8514472
Drug: Minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline hydrochloride injection after cyst aspiration
Trial: 14667889
Drug: DHEA (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (25 mg/d orally)
Trial: 30670642
Drug: Risperidone (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (dopamine antagonist)
Trial: 12644340
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (angiography only for patients with recurrent ischemia at rest or a positive stress test) with tirofiban (for 48 h) plus aspirin and heparin
Trial: 9640159
Drug: 0.375% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% ropivacaine 1.0 ml kg‐1
Trial: 9640159
Drug: 0.375% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine 1.0 ml kg‐1
Trial: 30551218
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of antidepressants
Trial: 23015748
Drug: Adjunctive antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antidepressant treatment
Trial: 18808424
Drug: Levetiracetam therapy
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam therapy
Trial: 11137250
Drug: AlPO(4)‐adjuvated vaccine/2+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AlPO(4)‐adjuvated vaccine/2+1 schedule
Trial: 11137250
Drug: AlPO(4)‐adjuvated vaccine/3+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AlPO(4)‐adjuvated vaccine/3+1 schedule
Trial: 11137250
Drug: Al(OH)(3)‐adjuvated vaccine/2+1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al(OH)(3)‐adjuvated vaccine/2+1 schedule
Trial: 9085953
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.02 mg/mL
Trial: 9085953
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HM) 0.075 mg/mL + Nalbuphine (NB) 0.08 mg/mL
Trial: 9085953
Drug: Hydromorphone (HM)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (HM) 0.075 mg/mL
Trial: 8280544
Drug: Diamorphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 2.5 mg in saline 10 ml
Trial: 8280544
Drug: Diamorphine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 2.5 mg in 1:200,000 adrenaline 10 ml
Trial: 31317471
Drug: 200 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg/day selenium supplements as selenium yeast
Trial: 27484082
Drug: Adjunctive steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive steroid (triamcinolone acetonide) given at the time of surgery (4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml sub‐Tenon's).
Trial: 27484082
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical treatment and care (control group).
Trial: 20626379
Drug: Brief detoxification
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief detoxification treatment (DETOX)
Trial: 20626379
Drug: Extended buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended buprenorphine-naloxone (BUP) treatment
Trial: 18058832
Drug: Galantamine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Trial: 18058832
Drug: Placebo augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Trial: 12534638
Drug: Meloxicam administered
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam administered once daily for 3 weeks or 6 months at doses between 7.5 and 60 mg
Trial: 8705294
Drug: Transferrin receptor
RxNorm normalized name: Transferrin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transferrin receptor in brain tissues from AD patients
Trial: 6897039
Drug: Oral molsidomine
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral molsidomine 4 mg
Trial: 6510452
Drug: Sustained-release isosorbide
RxNorm normalized name: isosorbide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release isosorbide dinitrate (ISDN) 40 mg
Trial: 22059409
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of selected lactobacilli up to the 24th to 26th week of gestation
Trial: 19037804
Drug: Capsinoids (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoids (15 mg/person)
Trial: 19037804
Drug: Capsinoids (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoids (30 mg/person)
Trial: 19037804
Drug: Capsinoids (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsinoids (15 or 30 mg/person)
Trial: 16935685
Drug: As-needed terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As-needed terbutaline (0.4 mg)
Trial: 12617263
Drug: Interferon-beta-1a (Rebif)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a (Rebif) treatment
Trial: 10871468
Drug: High-dose magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose magnesium sulfate (5 g/h)
Trial: 10871468
Drug: Low-dose magnesium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose magnesium sulfate (2 g/h)
Trial: 4007253
Drug: Adsorbed tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbed tetanus vaccine from source 1
Trial: 4007253
Drug: Adsorbed tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbed tetanus vaccine from source 2
Trial: 17082219
Drug: Radical prostatectomy
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical prostatectomy plus endocrine therapy